1. Home
  2. EQR vs NTRA Comparison

EQR vs NTRA Comparison

Compare EQR & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equity Residential of Beneficial Interest

EQR

Equity Residential of Beneficial Interest

HOLD

Current Price

$61.05

Market Cap

24.3B

Sector

Real Estate

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$198.26

Market Cap

28.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQR
NTRA
Founded
1993
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.3B
28.0B
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
EQR
NTRA
Price
$61.05
$198.26
Analyst Decision
Buy
Strong Buy
Analyst Count
13
14
Target Price
$69.42
$259.07
AVG Volume (30 Days)
2.0M
1.1M
Earning Date
05-07-2026
05-19-2026
Dividend Yield
4.58%
N/A
EPS Growth
8.09
0.65
EPS
2.94
N/A
Revenue
$2,701,075,000.00
$210,939,000.00
Revenue This Year
$4.33
$16.65
Revenue Next Year
$3.07
$19.22
P/E Ratio
$20.59
N/A
Revenue Growth
4.76
N/A
52 Week Low
$58.38
$125.38
52 Week High
$72.65
$256.36

Technical Indicators

Market Signals
Indicator
EQR
NTRA
Relative Strength Index (RSI) 44.28 43.74
Support Level $59.04 $194.03
Resistance Level $62.54 $251.09
Average True Range (ATR) 1.20 8.26
MACD -0.30 -0.05
Stochastic Oscillator 32.91 39.88

Price Performance

Historical Comparison
EQR
NTRA

About EQR Equity Residential of Beneficial Interest

Equity Residential owns a portfolio of 318 apartment communities with over 86,000 units and is developing three additional properties with 935 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: